Long-term survival results after treatment for oligometastatic brain disease by Nieder, Carsten et al.
 
 
Long-term survival results after treatment for oligometastatic brain disease  
 
Carsten Nieder, MD1,2; Mandy Hintz3; Ilinca Popp, MD3,4; Angelika Bilger, MD3,4;  Anca 
L. Grosu, MD3,4  
 
1Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, 
Norway 
2Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, 
9037 Tromsø, Norway 
3Department of Radiation Oncology, University Hospital Freiburg, 79106 Freiburg, 
Germany 




Corresponding author: Carsten Nieder, MD, Department of Oncology and Palliative 
Medicine, Nordland Hospital, 8092 Bodø, Norway, Tel: +47 75 57 8449, FAX: +47 75 








Aim: The aim of this study was to characterize the survival results of patients with up 
to four brain metastases after intense local therapy (primary surgery or stereotactic 
radiotherapy) if extracranial metastases were absent or limited to one site, e.g. the 
lungs.      
Background: Oligometastatic disease has repeatedly been reported to convey a 
favorable prognosis.  
Material and Methods: This retrospective study included 198 German and Norwegian 
patients treated with individualized approaches, always including brain radiotherapy. 
Information about age, extracranial spread, number of brain metastases, performance 
status and other variables was collected. Uni- and multivariate tests were performed.    
Results: Median survival was 16.5 months (single brain metastasis) and 9.8 months 
(2-4, comparable survival for 2, 3 and 4), respectively (p=0.001). After 5 years, 15 and 
2% of the patients were still alive. In patients alive after 2 years, added median survival 
was 23 months and the probability of being alive 5 years after treatment was 26%. In 
multivariate analysis, extracranial metastases were not significantly associated with 
survival, while primary tumor control was.       
Conclusion: Long-term survival beyond 5 years is possible in a minority of patients with 
oligometastatic brain disease, in particular those with single brain metastasis. The 
presence of extracranial metastases to one site should not be regarded a barrier 
towards maximum brain-directed therapy.                      
 





Background and Aim 
Current research has indicated that oligometastatic cancer is a disease state that 
should be differentiated from the more common state of disseminated distant spread, 
and that surgery or other ablative treatments might have a positive impact on 
prognosis.1-4 In the context of oligometastases to the brain without leptomeningeal 
seeding it has long been recognized that effective local therapy often translates into 
survival beyond the typical landmark of 1-2 years.5-8 Commonly, up to four brain 
metastases are regarded suitable targets for local therapy, such as stereotactic 
radiosurgery (SRS), stereotactic fractionated radiotherapy (SFRT) and surgical 
resection.9-11 The latter is often supplemented by post-operative stereotactic 
radiotherapy,12 while whole-brain radiotherapy (WBRT) is deferred until more 
widespread metastases become apparent. In case of negative prognostic factors, such 
as extensive and uncontrollable extracranial disease, WBRT or even best supportive 
care alone might be appropriate even in situations with up to four brain metastases.13,14 
The aim of the present study was to characterize the survival results of patients with 
up to four brain metastases after intense local therapy (primary surgery, SRS or SFRT) 
if extracranial metastases were absent or limited to one site, e.g. the lungs. We 
hypothesized that the combination of favorable disease extent and efficacious local 
treatment would lead to detectable 5-year survival, comparable to studies of 
oligometastases not involving the brain.         
 
Material and Methods 
Patients and treatment 
A retrospective study based on chart review of 198 patients with 1-4 irradiated brain 
metastases was performed. Patients managed with best supportive care or WBRT 
 
 
rather than surgery, SRS or SFRT were excluded. The same applies to patients with 
extracranial metastases to more than one site, meaning that those with adrenal gland 
metastases were eligible, while those with adrenal gland plus lung metastases were 
not. Patients with pleural or peritoneal metastases were not included. The number of 
extracranial metastases was not limited, because the imaging studies and intervals 
were not standardized in this real-world patient cohort. Staging was done as judged 
appropriate by the oncologists at the time of diagnosis of brain metastases. PET 
imaging was not mandatory and therefore the registered number of metastases might 
not always have been accurate enough when applying a common threshold for 
oligometastases, such as five metastases in total. We felt that a simple measure of 
extracranial disease extent, i.e. maximum one site, would be a reliable parameter to 
include for evaluation in this study. Moreover, in resource-limited settings extensive 
and advanced staging might not be feasible in clinical routine. The vast majority of 
patients never received ablative treatments, such as stereotactic body radiotherapy, 
for extracranial metastases. Brain-directed treatment was individualized and consisted 
of the aforementioned focal therapies with or without WBRT, or postoperative 
SRS/SFRT. Sequential salvage treatment of new or progressive intracranial lesions 
was individualized, too. All approaches mentioned above were considered at the time 
of relapse or progression. Systemic treatment before and after brain-directed 
measures was usually prescribed as judged appropriate by the patients’ medical 
oncologists. The patients were treated between 2000 and 2018 and identified from a 
previously described database, which includes data from the radiotherapy centers in 





Actuarial survival from the first day of radiotherapy or from surgery was calculated 
employing the Kaplan-Meier method, and different groups were compared using the 
log-rank test (SPSS 25, IBM Corp., Armonk, NY, USA). Date of death was known in all 
but 29 patients. The latter were included as censored observations after a median 
follow-up of 25 months (range 2-160). Uni- and multivariate Cox regression analysis 
was also performed (forward conditional method). The multivariate model included 
baseline patient characteristics that had p-values <0.05 in univariate analysis, but not 




Most patients (73%) had brain metastases alone. In 71% a single lesion was present 
on the treatment planning magnetic resonance imaging scans. Treatment included 
surgical resection in 78%. As shown in Table 1 non-small cell lung cancer (NSCLC) 
and breast cancer were common primary tumors. 
 
Survival 
Median survival was 16.5 months after treatment for single brain metastases (two: 9.6 
months, three: 11.9 months, four: 9.8 months, pooled 9.8 months). As shown in Figure 
1, five-year survival was 15 and 2%, respectively (log-rank test p=0.001). The 
differences regarding two, three or four brain metastases were not statistically 
significant (all p-values >0.11). Conditional survival was evaluated, too (based on 54 
patients who were alive two years after treatment). Their probability of being alive five 
years after treatment was 26%, and added median survival was 23 months.  
 
 
The presence of extracranial metastases worsened median survival (16.0 versus 10.5 
months, p=0.01). These results were obtained for the subgroup with single metastasis 
(18.0 versus 13.2 months) and 2-4 metastases (14.0 versus 9.5 months). However, 
different sites of extracranial metastases had different impact on survival, as shown in 
Figure 2. Survival was worst in patients with hepatic metastases (median 5.3 months), 
intermediate in those with pulmonal, lymphatic or osseous metastases (median 11.9 
months) and best in those with adrenal, cutaneous or subcutaneous/soft tissue 
metastases (median 16.3 months). The latter figure was similar to that seen in the 
absence of extracranial metastases (median 16.0 months, p=0.19).    
Controlled primary tumors were associated with better median survival (16.0 versus 
11.0 months, p=0.02). Primary disease type was also associated with survival, as 
shown in Table 2. Prognostic factors also included age (p=0.002 in the univariate Cox 
model) and Karnofsky performance status (KPS, p=0.0001 in the univariate Cox 
model), whereas time interval (p=0.29, log-rank test) and gender was not significant 
(p=0.78, log-rank test).  
Systemic therapy after local treatment was associated with improved survival (median 
14.5 versus 9.0 months, p=0.04). Surgery and SRS resulted in comparable outcome 
(median 16.0 versus 13.3 months, p=0.98).  
The multivariate model (Table 3) identified better KPS (p=0.0001), single brain 
metastasis (p=0.0001), primary tumor other than colon, bladder or unknown (p=0.008), 
younger age (p=0.009), and controlled primary tumor (p=0.014) as independent 
prognostic factors for survival. Irrespective of different ways of stratification, 






This study mainly included patients with single brain metastasis (71%), whose 
management included surgical resection with or without post-operative radiotherapy 
(78%). Seventy-three percent had brain metastases alone, the others extracranial 
metastases to one site without peritoneal or pleural involvement. In 25 cases (13%), 
these extracranial lesions were located in the lungs. The exact number of extracranial 
metastases was not included in this analysis, due to considerations and limitations 
already outlined. We believe this simple and straightforward approach towards 
definition of limited extracranial spread facilitates evaluation of retrospective databases 
that include information from staging methods, which evolved over time. In addition, it 
limits the resource utilization during staging or re-staging of these patients in clinical 
practice where the diagnosis, e.g., of small lung nodules that are difficult to biopsy or 
characterize on PET scans poses challenges. The study cohort was heterogeneous 
regarding type of primary tumor, time interval between cancer diagnosis and detection 
of brain metastases, age etc., and included a real-world population managed at two 
academic hospitals (all comers).  
 
In line with our hypothesis, a subgroup of patients survived for five or more years, in 
particular if single brain metastases were treated. Otherwise, the number of brain 
metastases (2, 3 or 4) did not significantly influence survival. Interestingly, multivariate 
analysis revealed that the apparent role of extracranial metastases diminished if other 
prognostic factors were considered as well. Eventually, primary tumor type and control 
were more important, besides well-established parameters, such as KPS and age. 
Unknown primary tumors (4%) were classified as uncontrolled. Seemingly, the pattern 
of extracranial spread impacted survival (worst in case of liver involvement). However, 
 
 
since these results were derived from small subgroups and did not persist in 
multivariate analysis additional work is needed to draw firm conclusions. At present, 
we recommend to consider surgery, SRS or SFRT also in patients with limited 
extracranial metastases, as defined in this study. In parallel, WBRT with simultaneous 
integrated dose escalation on multiple brain metastases is under investigation.15  
 
It is important to note that few patients received local treatment of their extracranial 
metastases. Rather, systemic therapy was administered. Unfortunately, the latter was 
not documented sufficiently in a considerable number of cases. In those with available 
information, systemic therapy was associated with better survival, comparable to a 
previous study that included patients treated with WBRT.16 Most patients were treated 
before immune checkpoint inhibitors became clinically available. Compared to other 
parts of the world, few of our patients with NSCLC were eligible for targeted therapy, 
due to absence of relevant targets. It is therefore tempting to speculate that 
contemporary management might be able to improve the long-term survival results 
further.17                 
 
There is additional evidence from other studies supporting the present findings. For 
example, a multi-center study from the United States and Canada (SRS, 2083 patients, 
many (46%) with lung primaries, 14% without extracranial metastases) demonstrated 
a median survival of 14.6 months (single brain metastasis) and 9.5 months (2-4 
metastases).18 Patients with 2-4 metastases had a significantly higher risk of distant 
brain failure. This endpoint was not included in our analysis. Compared to no 
extracranial metastases, oligometastases (max.5) were associated with significantly 
worse survival (HR 1.47 in multivariate analysis). However, this definition does not take 
 
 
into account number of involved organs or sites and is not directly comparable to our 
approach and eligibility criteria. In the future, additional strategies might improve 
identification of patients with limited extracranial disease burden, e.g. liquid biomarkers 
and surrogates of impaired organ function.19,20 
        
For patients with breast cancer, a Polish study reported median survival of 20 months 
in the setting of a solitary brain metastasis (i.e., no extracranial spread) and 11 months 
for patients with single brain metastases.21 In our combined group (n=21, too small to 
stratify), the corresponding figure was 13 months. Kotecha et al. have also shown that 
5-10 year survival is possible, especially if solitary or single brain lesions were 
present.22 Despite these encouraging data, non-brain oligometastases seemingly fare 
better. After stereotactic radiotherapy of pulmonary oligometastases (max.5, max.2 
organs) median survival was 33 months and 5-year survival 30%.23 In a different study 
(surgery or radiotherapy, lung oligometastases) 5-year survival was about 40% for both 
modalities.24 A 5-year survival rate of 32% was reported by Wong et al. (max.5 
metastases, stereotactic radiotherapy).25 Possibly, differences in tumor biology might 
explain these results (predominant brain seeding vs. affinity to other sites).26 Even if 
retrospective studies suffer from limitations and possible selection bias, the aggregate 
data suggests that it is important for clinicians to perform a comprehensive assessment 
of management options in patients with brain metastases who have the potential to 
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Figure 1. Actuarial overall survival (Kaplan-Meier analysis) stratified by number of brain 




Figure 2. Actuarial overall survival (Kaplan-Meier analysis) stratified by extracranial 
metastases: none, favourable (adrenal, cutaneous, subcutaneous/soft tissue), 
intermediate (pulmonal, osseous, lymphatic), unfavourable (hepatic), p=0.19 (none 
versus favourable), p<0.05 for unfavourable versus each of the remaining groups and 
also for intermediate versus each of the remaining groups. Number of patients: 144 





Table 1. Baseline characteristics in 198 patients 
Parameter number percent 
Single brain metastasis 141 71 
Two brain metastases 29 15 
Three brain metastases 22 11 
Four brain metastases 6 3 
No extracranial metastases 144 73 
One extracranial site involved 54 27 
Controlled primary tumor 134 68 
Uncontrolled primary tumor 62 31 
Unknown status of the primary tumor 2 1 
Surgical resection 154 78 
Stereotactic radiosurgery 30 15 
Stereotactic fractionated radiotherapy 14 7 
Non-small cell lung cancer 90* 45 
Breast cancer 21 11 
 
 
Kidney cancer 18 9 
Colon cancer 14 7 
Malignant melanoma 13 7 
Rectal cancer 10 5 
Unknown primary tumor 7 4 
Small cell lung cancer 6 3 
Ovarian cancer 5 3 
Others 14 7 
Female sex 106 54 
Male sex 92 46 
Synchronous brain metastases 63 32 
Presentation within 12 months 46 23 
Interval 13-35 months 46 23 
Interval at least 36 months 26 13 
Metachronous, undocumented interval 17 9 
Systemic treatment after local therapy 65 33 
 
 
No systemic treatment 36 18 
Lack of definitive information 97 49 
Median age, years, range 63 25-85 
Median Karnofsky performance status 80 60-100 




Table 2. Median overall survival (OS) stratified by primary tumor 
Tumor Median OS 
Small cell lung cancer 19.0 
Ovarian cancer 19.0 
Rectal cancer 17.5 
Malignant melanoma 16.3 
Kidney cancer 16.0 
Non-small cell lung cancer (others, mixed, unspecified) 15.0 
Non-small cell lung cancer (squamous cell)  14.0 
Non-small cell lung cancer (adenocarcinoma) 13.7 
Breast cancer 13.0 
Unknown primary 6.4 
Bladder cancer 5.4 





Table 3. Prognostic factors for overall survival  
Parameter Univariate p-value Multivariate p-value Hazard ratio 
Age, continuous 0.002 0.009 1.02 
KPS, continuous 0.0001 0.0001 0.61 
Single brain metastasis 0.001 0.0001 0.52 
Any extracranial metastases present 0.01 0.09 n.s. 
Controlled primary tumor 0.02 0.014 0.62 
Primary tumor colon, bladder or unknown 0.001 0.008 1.72 
Gender 0.78   
Time interval 0.29   
    
KPS: Karnofsky performance status, n.s.: not significant 
 
